Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: A prospective study*
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Since immunomodulators and antitumor necrosis factor (TNF) agents are increasingly used to treat inflammatory bowel disease (IBD), it is recommended to administer antipneumococcal vaccination to prevent opportunistic pneumonia. There is some evidence that concomitant immunosuppression may impair the immune response to vaccination. We aimed to evaluate the response rates to pneumococcal vaccination in four different treatment groups (mesalamine, azathioprine, infliximab, infliximab plus azathioprine). METHODS: In all, 96 patients with IBD (54 with Crohn's disease; 42 with ulcerative colitis) were administered a 23-valent polysaccharide pneumococcal vaccine (PSV-23). The levels of antipneumococcal antibodies were measured prior to and at least 3 weeks after vaccination. Response rates and risk factors for impaired immunosuppression were investigated. Patients on mesalamine were used as a control group. RESULTS: Patients administered infliximab or the combination immunosuppressive therapy had significantly lower response rates to vaccination (57.6% and 62.5%, respectively) compared with the group on mesalamine (88.6%; P < 0.05 for both comparisons). Azathioprine alone did not influence the response rate to vaccination (78.9%; P = 0.43 vs. mesalamine group). Mean antibody titers after vaccination were significantly lower in patients under infliximab or combined immunosuppression than controls (P < 0.05). Immunosuppression with infliximab or combination therapy significantly decreased the likelihood of responding to vaccination (odds ratio [OR] = 0.17, 95% confidence interval [CI] 0.04-0.64, P = 0.009, and OR = 0.21, 95% CI 0.05-0.91, P = 0.038, respectively). Pneumococcal vaccination was generally safe and well tolerated. CONCLUSIONS: Anti-TNF therapy alone or in combination with azathioprine impairs the response to pneumococcal vaccination in patients with IBD. All patients with IBD should therefore be vaccinated before starting anti-TNF therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Satsangi, J., Silverberg, M. S., Vermeire, S., & Colombel, J.-F. (2006) · Gut · doi:10.1136/gut.2005.082909 · Cited by 3,176 · cited 4×
“The level of clinical disease activity was assessed using the Harvey–Bradshaw index (HBI) for CD19 and the Mayo Clinic subscore for UC.20 No endoscopic assessment of disease activity was requested for the study.”
MethodInfluentialInfliximab, Azathioprine, or Combination Therapy for Crohn's Disease
Colombel, J. F., Sandborn, W. J., Reinisch, W., Mantzaris, G. J., Kornbluth, A., Rachmilewitz, D., Lichtiger, S., D'Haens, G., Diamond, R. H., Broussard, D. L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0904492 · Cited by 3,143 · cited 2×
“As an alternative to steroids, the combination of azathioprine and infliximab seems to be more effective than immunosuppressive monotherapy in increasing the chances of therapeutic response in patients with active CD.(4) Prolonged and continued pharmacological immunosuppression in patients with IBD can cause some adve…”
BackgroundA SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY
Harvey, R. F., & Bradshaw, J. M. (1980) · The Lancet · doi:10.1016/s0140-6736(80)92767-1 · Cited by 2,959
Dignass, A., Van Assche, G., Lindsay, J. O., Lémann, M., Söderholm, J., Colombel, J. F., Danese, S., D'Hoore, A., Gassull, M., Gomollón, F., et al. (2010) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.12.002 · Cited by 1,498 · cited 1×
“Recent European guidelines recommend the use of steroids as the first-choice approach to treating CD, as well as suggesting early introduction of immunomodulators or biological agents such as antitumor necrosis factor (TNF) to minimize prolonged steroid use and in the case of relapse.(3) As an alternative to steroids,…”
BackgroundSelf-citationRisk Factors for Opportunistic Infections in Patients With Inflammatory Bowel Disease
Toruner, M., Loftus, E. V., Harmsen, W. S., Zinsmeister, A. R., Orenstein, R., Sandborn, W. J., Colombel, J., & Egan, L. J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.012 · Cited by 1,017 · cited 1×
“Prolonged and continued pharmacological immunosuppression in patients with IBD can cause some adverse events, particularly the increased risk of opportunistic infections, which can even be fatal.(5) Bacterial, viral, and fungal infections can be potentially dangerous during the course of immunosuppression, and accurat…”
BackgroundRahier, J. F., Ben-Horin, S., Chowers, Y., Conlon, C., De Munter, P., D'Haens, G., Domènech, E., Eliakim, R., Eser, A., Frater, J., et al. (2009) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.02.010 · Cited by 738 · cited 2×
“strongly recommend vaccination against potentially severe infectious agents, such as influenza, pneumococcus, and the hepatitis B virus (HBV).(6,7) Streptococcus pneumoniae is the most common cause of community-acquired pneumonia, and causes up to 500,000 cases of pneumonia a year in the United States.”
BackgroundMethodInfections in patients with rheumatoid arthritis treated with biologic agents
Listing, J., Strangfeld, A., Kary, S., Rau, R., von Hinueber, U., Stoyanova‐Scholz, M., Gromnica‐Ihle, E., Antoni, C., Herzer, P., Kekow, J., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21386 · Cited by 681 · cited 1×
“However, immunocompromised patients are at an increased risk of developing pneumococcal pneumonia, which can cause up to 25% of deadly infections in patients with chronic immune-mediated diseases requiring prolonged immunosuppression.(10,11) Importantly, there is an increased risk of pneumococcal pneumonia in patients…”
BackgroundSutherland, L. R., Martin, F., Greer, S., Robinson, M., Greenberger, N., Saibil, F., Martin, T., Sparr, J., Prokipchuk, E., & Borgen, L. (1987) · Gastroenterology · doi:10.1016/0016-5085(87)90621-4 · Cited by 677 · cited 4×
“The level of clinical disease activity was assessed using the Harvey–Bradshaw index (HBI) for CD19 and the Mayo Clinic subscore for UC.20 No endoscopic assessment of disease activity was requested for the study.”
MethodInfluentialAskling, J., Fored, C. M., Brandt, L., Baecklund, E., Bertilsson, L., Feltelius, N., Cöster, L., Geborek, P., Jacobsson, L. T., Lindblad, S., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.062760 · Cited by 334 · cited 1×
“Importantly, there is an increased risk of pneumococcal pneumonia in patients with IBD and prevention by vaccination is thus strongly recommended.(12) Vaccination should be done as early as possible, as the risk of opportunistic infections increases following the first year of pharmacological immunosuppression.”
BackgroundEtiopathogenesis of inflammatory bowel diseases
Danese, S., & Fiocchi, C. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.12.4807 · Cited by 327
Self-citation
Cited by
Magro, F., Gionchetti, P., Eliakim, R., Ardizzone, S., Armuzzi, A., Barreiro-de Acosta, M., Burisch, J., Gecse, K. B., Hart, A. L., Hindryckx, P., et al. (2017) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjx008 · Cited by 1,910
Kucharzik, T., Ellul, P., Greuter, T., Rahier, J. F., Verstockt, B., Abreu, C., Albuquerque, A., Allocca, M., Esteve, M., Farraye, F. A., et al. (2021) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjab052 · Cited by 480
ACG clinical guideline: Preventive care in inflammatory bowel disease
Farraye, F. A., Melmed, G. Y., Lichtenstein, G. R., & Kane, S. V. (2017) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.537 · Cited by 473
Clinical use of anti-TNF therapy and increased risk of infections
Ali, T., Bronze, Kaitha, Mahmood, Ftaisi, & Stone (2013) · Drug, Healthcare and Patient Safety · doi:10.2147/dhps.s28801 · Cited by 242
“Anti-TNF therapy may impair the response to pneumococcal vaccination, so the vaccine is usually recommended $ 2–3 weeks prior to starting antiTNF therapy.(41)”
Immunogenicity and mechanisms impairing the response to vaccines in inflammatory bowel disease
Marín, A. C. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i40.11273 · Cited by 58
Metadata
- Authors
- Fiorino, G., Peyrin-Biroulet, L., Naccarato, P., Szabò, H., Sociale, O. R., Vetrano, S., Fries, W., Montanelli, A., Repici, A., Malesci, A., & Danese, S.
- Venue
- Inflammatory Bowel Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-06
- Volume
- 18
- Issue
- 6
- Pages
- 1042-1047
- ISSN
- 1078-0998 (ISSN-L)
- OpenAlex
- W2131198668
- Cited by
- 177
- References
- 24
- FWCI
- 4.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.